Circulating Osteoclast Precursors as Markers of Bone Resorption in Inflammatory Arthritis
URV Reference Number:
The invention is a cell culture assay of a subject's circulating peripheral blood mononuclear cells (PBMC) to determine the number of osteoclast precursors among those cells.
This technology can determine whether inflammatory arthritis patients are at increased risk for bone erosion and can be used to test the efficacy of therapeutic agents in inflammatory arthritis (diagnosis and monitoring of therapy) and may be useful in other rheumatoid and autoimmune conditions such as Crohn?s disease, psoriasis, rheumatoid arthritis, and ankylosing spondylitis.
There are currently no accepted methods for early evaluation of and prediction of which patients are at the most risk for erosive bone disease, and there is currently no method that can demonstrate early in the course of therapy whether the therapeutic approach will work. This technology has the advantage of using a biomarker that is correlated to a later outcome of therapy.
Methods and Compositions Related to Joint Inflammation Diseases
Bookmark this page
Download as PDF
For Information, Contact:
University of Rochester
© 2017. All Rights Reserved. Powered by